Source: International Congress 2014 – New diagnostics and better treatments for multidrug and extensively drug-resistant tuberculosis (M/XDR-TB)
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Saukkonen (West Roxbury, United States of America). The impact of drug resistance on TB control and elimination. International Congress 2014 – New diagnostics and better treatments for multidrug and extensively drug-resistant tuberculosis (M/XDR-TB)

Member's Comments

No comment yet.

Related content which might interest you: Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 The problem of one drug resistance in tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 858s Year: 2006 Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Evolution of TB control and elimination strategies Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 The problem of multi-drug resistant (MDR)-TB Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005